All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your PsOPsA Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB and Bristol Myers Squibb: For educational content and news updates.
New and emerging therapies for psoriatic arthritis
By Ella Dixon
Featured
At the European Alliance of Associations for Rheumatology (EULAR) Congress 2024, our steering committee member Peter Nash, Griffith University, Queensland, AU, interviewed Alvin Wells, a rheumatologist in Chicago and Milwaukee, US, about new and emerging therapies for psoriatic arthritis (PsA).
New and emerging therapies for psoriatic arthritis
Wells discusses how therapy options have improved over recent years, with the introduction of interleukin (IL), Janus kinase (JAK), and tyrosine kinase 2 (TYK2) inhibitors. He also speaks about the use of JAK inhibitors in PsA, their approvals, and how he uses these in his practice. Finally, Wells talks about the potential of chimeric antigen receptor (CAR) T-cell therapies in PsA.
Your opinion matters
6 votes - 80 days left ...
Related articles
Newsletter
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox